Opendata, web and dolomites

BREAK SIGNED

Blue light remote analgesia with K+ channels

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREAK project word cloud

Explore the words cloud of the BREAK project. It provides you a very rough idea of what is the project "BREAK" about.

stakeholder    causing    cells    hard    protein    adoption    proteins    drugs    patients    worse    situation    adults    stimuli    solution    skin    interpret    distance    hours    area    inhibitory    invasiveness    thirds    neuropathic    lower    opioids    initiated    silencing    exact    abnormal    minutes    difficult    neuron    kept    painful    pain    class    weeks    invasive    academic    despite    brain    investor    companies    population    chronic    actually    originally    cm    gt    extremely    spectrum    plan    disorder    origin    medical    illness    central    mostly    treatments       hospitals    diagnose    nervous    blink2    commercial    constitute    break    antidepressants    engineered    optical    first    explore    entities    reporting    nonspecific    normally    peripheral    nausea    pharma    implant    leveraging    treat    tool    designed    optogenetic    leads    centers    prolonged    blue    demonstrated    partial    drug    trauma    np    virus    version    global    vivo    restraining    treatment    rats    damage    fruitful    injected    genes    relief    20    addiction    network    characterised    cp    experiments    device    light    synergy    lamp    12    genetically    progress   

Project "BREAK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 150˙000.00

Map

 Project objective

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More